This theory was tested in an elegant in vivo study, in which a BRN2 reporter (GFP) and cellular pigmentation (as surrogate marker for MITF expression) were analysed during B16F2 melanoma progression (Pinner et al., 2009). This evidence concerns the gene POU3F2 and melanoma.